- Multiple breakthroughs in the field of onco-immunology are expected over the next 20 years
- BriaCell Therapeutics Corp. is a frontrunner in this area, as it has already established proof of concept for its Bria-IMT solution for advanced breast cancer patients
- The company is also developing Bria-OTS, a personalized off-the-shelf solution, that will be much easier and less costly to manufacture than comparable personalized immunotherapies
According to a report published in the British Society of Immunology, a new era has begun in the battle against cancer, as the development of immunotherapies for malignancies will take cancer treatments to a whole new level (http://ibn.fm/FRJZN). Several companies, including BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), are leading the way.
The British Society of Immunology article, part of a wider report marking 60 years of immunology, takes a brief look at the history of immunotherapies used to treat cancer, as well as the biggest limitations and expectations for the future. According to the report, this next era of cancer treatment had a major turning point with the development of monoclonal antibodies, followed by attempts to redesign T-cells, one of the body’s most important cancer fighting units. Many efforts now are directed toward the preventative aspects of immunotherapies in hope of developing a vaccine-based cure for cancer by 2020.
According to Frontiers of Immunology, a stream of breakthroughs will be observed in the field over the next 20 years (http://ibn.fm/eEbww). Immunotherapeutic approaches will be enhanced and selectively combined to help the immune system target malignancies without causing needless toxicities.
The global cancer immunotherapy market currently holds approximately 50 percent of the entire oncology therapeutics market. It generated $54 billion in 2016 and is expected to reach more than $100 billion by 2022 (http://ibn.fm/bPdce).
By 2026, immunotherapy solutions are anticipated to become the treatment of choice for various types of cancer. Estimates suggest that approximately 60 percent of previously-treated cancer patients will likely adopt an immunotherapeutic approach within this timeframe.
BriaCell Therapeutics Corp. is a Berkeley-based clinical-stage biotechnology company that’s currently focused on the development of targeted immunotherapy solutions for advanced breast cancer patients. Its primary candidate, Bria-IMT, has demonstrated excellent results in several clinical trials to date.
Bria-IMT works by providing breast cancer antigens. In addition, the treatment directly stimulates the T-cells to maximize their anti-cancer capabilities. Bria-IMT has already achieved proof of concept in clinical trials, with its safety and tolerability assessed as excellent. The effectiveness of the immunotherapy is high, as it managed to elicit tumor regression even in the case of heavily pre-treated advanced breast cancer patients.
The latest research outcomes have resulted from a combined study of Bria-IMT and KEYTRUDA (pembrolizumab) by Merck & Co. Inc. (NYSE: MRK). The combination was well tolerated in all six patients participating in the trial. This clinical trial is ongoing, and additional information about the outcomes will be provided in the first quarter of 2019, according to BriaCell Therapeutics Corp.
Apart from subjecting Bria-IMT to strenuous clinical trials, BriaCell Therapeutics Corp. is also working on the development of Bria-OTS – a personalized off-the-shelf immunotherapy solution for advanced breast cancer patients. Bria-OTS will be the first personalized immunotherapeutic solution to offer cost-effectiveness and an easier manufacturing process when compared to existing therapies.
Upon its development, Bria-OTS is expected to cover over 99 percent of the patient population. It is expected to deliver an immune response against the specific cancer tailored to each patient without necessitating a complex manufacturing and logistics process.
For more information, visit the company’s website at www.BriaCell.com